



**THE FOUNDATION  
FOR SECURE  
MARKETS**

#48469

**Date:** March 22, 2021

**Subject:** Neos Therapeutics, Inc. – Contract Adjustment  
Option Symbol: NEOS  
New Symbol: AYTU1  
Date: 03/22/21  
\* \* \* Update \* \* \*

**Contract Adjustment**

**Date:** March 22, 2021

**Option Symbol:** NEOS changes to AYTU1

**Strike Divisor:** 1

**Contracts Multiplier:** 1

**New Multiplier:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 2.50 yields \$250.00)

**New Deliverable Per Contract:**  
1) 10 Aytu Biopharma, Inc. (AYTU) Common Shares  
2) Cash in lieu of 0.88 fractional AYTU Common Shares

**CUSIP:** AYTU: 054754874

**Pricing**

Until the cash in lieu amount is determined, the underlying price for AYTU1 will be determined as follows:

$$\text{AYTU1} = 0.1088 (\text{AYTU})$$

**Delayed Settlement**

The AYTU component of the AYTU1 deliverable will settle at NSCC. The cash component of the AYTU1 deliverable will be subject to delayed settlement until the cash in lieu of fractional AYTU shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

**Background**

On March 18, 2021, Shareholders of Neos Therapeutics, Inc. (NEOS) voted concerning the proposed merger with Aytu BioScience, Inc. (AYTU). The merger was approved and subsequently consummated on

March 19, 2021. As a result, Aytu BioScience, Inc. will change its name to Aytu Biopharma, Inc., and each existing NEOS Common Share will be converted into the right to receive **0.1088 AYTU Common Shares**. Cash will be paid in lieu of fractional AYTU shares.

### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).